🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 95 of 116

  1. Entinostat

    Syndax Pharmaceuticals

    Neoplasms

    phase 1 small molecule completed

    2 trials

  2. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  3. Erwinase

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 1 small molecule completed

    1 trial

  4. Erwinia Chrysanthemi asparaginase

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule terminated

    1 trial

  5. Etrumadenant

    Arcus Biosciences

    Non Small Cell Lung Cancer Metastatic

    phase 1 small molecule completed

    1 trial

  6. Etrumadenant

    Arcus Biosciences

    TNBC - Triple-Negative Breast Cancer

    phase 1 small molecule completed

    1 trial

  7. Etrumadenant

    Arcus Biosciences

    Non-small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  8. Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.

    Disc Medicine

    Locally advanced rectal cancer

    phase 1 other active

    1 trial

  9. Evixapodlin

    Gilead Sciences Ireland UC

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  10. Evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Bladder Cancer

    phase 1 small molecule completed

    1 trial

  11. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  12. Ex-vivo expanded allogeneic γδ T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 1 mab active

    1 trial

  13. Ex-vivo expanded allogeneic γδT cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab active

    1 trial

  14. ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStatic prostate cancEr patients

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic prostate cancer

    phase 1 other active

    1 trial

  15. FATE-NK100

    Zafatek

    HER2 Positive Gastric Cancer

    phase 1 small molecule completed

    1 trial

  16. FHD-286

    Foghorn Therapeutics

    Metastatic Uveal Melanoma

    phase 1 small molecule terminated

    1 trial

  17. FHD-609

    Foghorn Therapeutics

    Advanced Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial

  18. FP-1039

    Prime Medicine

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  19. FPA144

    Prime Medicine

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  20. FPA150

    Prime Medicine

    Breast Cancer

    phase 1 mab terminated

    1 trial

  21. FPT155

    Prime Medicine

    Advanced Solid Tumors

    phase 1 mab terminated

    1 trial

  22. FT500

    Zafatek

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  23. FT516

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  24. FT516

    Zafatek

    Acute Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  25. FT522

    Zafatek

    Relapsed/Refractory B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  26. FT536

    Zafatek

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  27. FT538

    Zafatek

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  28. FT538

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  29. FT596

    Zafatek

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  30. FT596

    Zafatek

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  31. FT819

    Zafatek

    Lymphoma, B-Cell

    phase 1 small molecule active

    1 trial

  32. FT825

    Zafatek

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  33. FT836

    Zafatek

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  34. Fast Dual CAR-T Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Lymphoma

    phase 1 mab terminated

    1 trial

  35. First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers

    The George Institute

    Lynch Syndrome

    phase 1 other active

    1 trial

  36. First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

    The George Institute

    Relapsed/refractory B-cell aggressive lymphoma

    phase 1 other active

    1 trial

  37. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  38. First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

    Advanced Accelerator Applications

    Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy

    phase 1 other active

    1 trial

  39. First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

    OnKure Therapeutics

    Advanced Solid Tumors, Advanced Breast Cancer

    phase 1 other active

    1 trial

  40. First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  41. First-in-Human trial of DS9051b in participants with advanced solid tumors

    Daiichi Sankyo

    Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

    phase 1 other active

    1 trial

  42. First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  43. First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

    Genmab A/S

    Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  44. First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

    Turn Therapeutics

    Phase 1: Advanced solid tumors harboring genetic alterations in MET

    phase 1 other active

    1 trial

  45. First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  46. First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

    Bayer Australia Ltd

    Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression

    phase 1 other active

    1 trial

  47. First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

    Amgen

    Extensive Stage Small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  48. Follicle Stimulating Hormone Receptor T Cells

    Anixa Biosciences Inc

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.